Bausch Health Companies Inc.
CorpDigest
Bausch Health Companies Inc.
Company History
Founded 1994 in Laval, Quebec, Canada
Last reviewed: 2026-06-08 · By Swet Parvadiya
Bausch Health Companies Inc. generated $8.9 billion in FY2024 global revenue, operating as a highly leveraged, diversified specialty pharmaceutical enterprise that commands a 72% gross margin by focusing exclusively on high-margin patented therapeutics in gastroenterology, dermatology, and international branded generics. The company's strategic identity was defined through the May 2022 spin-off of Bausch + Lomb, a massive corporate divorce that eliminated a $3.8 billion revenue stream but permanently removed the complex intercompany debt guarantees that had paralyzed the balance sheet for a decade. This pivot has resulted in a highly concentrated portfolio where growth is now being driven by the rapid scaling of next-generation assets, including the first-in-class aryl hydrocarbon receptor agonist tapinarof for dermatology and the expansion of the Xifaxan franchise into new gastroenterology indications. With approximately 25,000 employees and a market capitalization of $2.5 billion, Bausch Health allocates $1.2 billion annually to R&D, funding a pipeline of over 30 clinical projects and enabling aggressive acquisitions in dermatology and microbiome therapies. The company's future depends on its ability to execute a 3-5% constant currency sales CAGR through 2030, a target that requires the successful commercial launch of its dermatology pipeline and the continuous expansion of its dominant position in gastroenterology to offset the impending patent cliffs of its core franchises and the relentless pressure of a $15.5 billion debt load.
J. Michael Pearson is a Canadian businessman and former CEO of Valeant Pharmaceuticals, who served as the company's chief executive from 2008 to 2016. He played a pivotal role in the company's aggressive expansion, navigating the complex debt financing structures provided by Pershing Square and Oaktree Capital to execute a series of transformational acquisitions. Pearson's background as a McKinsey consultant gave him a unique perspective on the pharmaceutical industry, driving his focus on financial engineering and cost-cutting rather than internal drug discovery. During his tenure, he oversaw the acquisition of over 50 companies, including Coria Laboratories, Medicis, and Salix Pharmaceuticals, which generated tens of billions of dollars in cumulative revenue. Pearson was also known for his controversial pricing strategies, which sparked public outrage and led to a massive SEC investigation and a 96% collapse in the company's stock price in 2015. Despite the controversy, Pearson is widely credited with transforming Valeant from a struggling niche player into a global pharmaceutical powerhouse, although his legacy is permanently tarnished by the regulatory and reputational damage caused by his aggressive tactics.
The corporate lineage of Bausch Health began with the founding of ICO Corporation in Canada, which later merged with Biolyse Pharma to form the foundation of the modern entity.
Biolyse Pharma changed its name to Valeant Pharmaceuticals, marking the beginning of the aggressive acquisition-driven strategy that would define the company for the next two decades.
Valeant acquired Coria Laboratories for $350 million, securing a diversified portfolio of dermatology brands and establishing a foothold in the lucrative topical therapeutics market.
Valeant merged with Biovail in a reverse merger transaction, creating a significantly larger entity with enhanced manufacturing capabilities and a broader international footprint.
Following a Citron Research short-seller report and a subsequent SEC investigation, Valeant's stock price collapsed by 96%, forcing the ousting of CEO J. Michael Pearson and the complete restructuring of the board.
Valeant acquired Salix Pharmaceuticals for $10.3 billion, securing the Xifaxan franchise and establishing a dominant position in the gastroenterology market.
Valeant Pharmaceuticals officially changed its name to Bausch Health Companies Inc., attempting to distance the corporate identity from the toxic legacy of the Valeant era.
Bausch Health acquired the Ortho Dermatologics portfolio from Johnson & Johnson for $800 million, significantly expanding its presence in the acne and psoriasis markets.
Bausch Health acquired Dermira for $1.2 billion, securing the proprietary olumacostat glasaretil asset and expanding its pipeline in the dermatology space.
Bausch Health completed the spin-off of its Bausch + Lomb eye care division, eliminating a $3.8 billion revenue stream but permanently removing the complex intercompany debt guarantees.
Bausch Health reported $8.9 billion in global revenue for FY2024, with operating income reaching $1.8 billion and free cash flow at $2.1 billion, demonstrating strong performance post-spin-off.
Bausch Health acquired Dermira for $1.2 billion to gain control of the proprietary olumacostat glasaretil asset, a first-in-class topical inhibitor of sebaceous lipase for the treatment of acne vulgaris.
Bausch Health acquired the Ortho Dermatologics portfolio from Johnson & Johnson for $800 million, securing a diversified portfolio of topical acne and psoriasis therapies, including Epsolay and Wynzora.
Valeant Pharmaceuticals acquired Salix Pharmaceuticals for $10.3 billion to gain control of the Xifaxan franchise, establishing a dominant position in the gastroenterology market.